# Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

> **NCT03953300** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 75 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Benralizumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03953300
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-08
- **Primary completion:** 2026-10-19
- **Final completion:** 2026-10-19
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03953300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03953300, "Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT03953300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*